Jeff Albers

Jeff Albers is CEO, President, and a member of the board of directors at Blueprint Medicines. Prior to this role, Jeff served as President of the Norwegian biotechnology company Algeta ASA and was head of all US operations. Previously, Jeff held senior commercial and corporate development positions at Genzyme, most recently as Vice President of the US Hematology and Oncology business unit, where his responsibilities included the US launch of Mozobil for mobilization of hematopoietic stem cells. Jeff holds a BS from Indiana University and an MBA and JD from Georgetown University.